Alizyme Alizyme
Nomura is leading a £30.5m capital increase for Alizyme, which develops treatments for obesity and gastrointestinal complaints.
Shareholders will be offered 30.5m shares in the company, equal to about 21% of its share capital, on a four-for-19 basis at a subscription price of 100p, a ...Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: subs@globalcapital.com
Or sign up for a trial to gain full access to the entire site for a limited period.
Corporate access
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.
